Serum MicroRNA-Based Risk Prediction for Stroke

被引:57
|
作者
Sonoda, Takumi [1 ]
Matsuzaki, Juntaro [1 ]
Yamamoto, Yusuke [1 ]
Sakurai, Takashi [2 ]
Aoki, Yoshiaki [4 ]
Takizawa, Satoko [5 ]
Niida, Shumpei [3 ]
Ochiya, Takahiro [1 ,6 ]
机构
[1] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan
[2] Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Aichi, Japan
[3] Natl Ctr Geriatr & Gerontol, Med Genome Ctr, Obu, Aichi, Japan
[4] Dynacom Co Ltd, Chiba, Japan
[5] Toray Industries Ltd, Kamakura, Kanagawa, Japan
[6] Tokyo Med Univ, Dept Mol & Cellular Med, Tokyo, Japan
关键词
biomarkers; cerebrovascular disorders; circulating microRNA; microarray analysis; serum; C-REACTIVE PROTEIN; EXTRACELLULAR VESICLES; BREAST-CANCER; BIOMARKERS; INFARCTION; MORTALITY;
D O I
10.1161/STROKEAHA.118.023648
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose Numerous studies have shown that circulating microRNAs (miRNAs) can be used as noninvasive biomarkers of various diseases. This study aimed to identify serum miRNAs that predict the risk of stroke. Methods The cases were individuals who had been diagnosed with cerebrovascular disorder by brain imaging. The controls were individuals with no history of stroke who had undergone a medical checkup. Serum miRNA profiling was performed for all participants using microarray analysis. Samples were divided into discovery, training, and validation sets. In the discovery set, which consisted of control samples only, serum miRNAs that correlated with the predicted risk of stroke, as calculated using 7 clinical risk factors, were identified by Pearson correlation analysis. In the training set, a discriminant model between cases and controls was constructed using the identified miRNAs, Fisher linear discrimination model with leave-one-out cross-validation and DeLong test. In the validation set, the predictive accuracy of the constructed model was calculated. Results First, in 1523 control samples (discovery set), we identified 10 miRNAs that correlated with a predicted risk of stroke. Second, in 45 controls and 87 cases (training set), we identified 7 of 10 miRNAs that significantly associated with cerebrovascular disorder (miR-1228-5p, miR-1268a, miR-1268b, miR-4433b-3p, miR-6090, miR-6752-5p, and miR-6803-5p). Third, a 3-miRNA combination model (miR-1268b, miR-4433b-3p, and miR-6803-5p) was constructed in the training set with a sensitivity of 84%, a specificity of 98%, and an area under the receiver operating characteristic curve of 0.95 (95% CI, 0.92-0.98). Finally, in 45 controls and 86 cases (validation set), the 3-miRNA model achieved a sensitivity of 80%, a specificity of 82%, and an area under the receiver operating characteristic of 0.89 (95% CI, 0.83-0.95) for cerebrovascular disorder. Conclusions We identified 7 serum miRNAs that could predict the risk of cerebrovascular disorder before the onset of stroke.
引用
收藏
页码:1510 / 1518
页数:9
相关论文
共 50 条
  • [41] Development of microRNA-based therapy for pancreatic cancer
    Fesler Andrew
    Ju Jingfang
    Department of Pathology
    胰腺病学杂志(英文), 2019, 02 (04) : 147 - 151
  • [42] MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer
    Pisarska, Justyna
    Baldy-Chudzik, Katarzyna
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 24
  • [43] A diagnostic microRNA-based test for the diagnosis of mesothelioma
    Benjamin, Hila
    Lebanony, Danit
    Tabak, Sarit
    Barabash, Naama
    Gibori, Hadas
    Morgenstern, Sara
    Meiri, Eti
    Bentwich, Zvi
    Rosenfeld, Nitzan
    Rosenwald, Shai
    Cohen, Dalia
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S347 - S347
  • [44] Exosomal microRNA-Based therapies for skin diseases
    Chen, Jibing
    Liang, Weiping
    Yang, Yuwei
    Feng, Bingzheng
    Xu, Zhiran
    REGENERATIVE THERAPY, 2024, 25 : 101 - 112
  • [45] Towards microRNA-based therapeutics for diabetic nephropathy
    M. L. Alvarez
    J. K. DiStefano
    Diabetologia, 2013, 56 : 444 - 456
  • [46] MicroRNA-based diagnostic assay for malignant mesothelioma
    Benjamin, Hila
    Lebanony, Danit
    Rosenwald, Shai
    Cohen, Lahav
    Shabes, Norberto
    Barabash, Naama
    Goren, Eran
    Leizerman, Hit
    Aharonov, Ranit
    Bentwich, Zvi
    Rosenfeld, Nltzan
    Cohen, Dalia
    CANCER RESEARCH, 2009, 69
  • [47] MicroRNA-based therapy for glioblastoma: Opportunities and challenges
    Lei, Qingchun
    Zhou, Wenhui
    Liu, Wenwen
    Li, Yixin
    Qi, Nanchang
    Li, Qiangfeng
    Ding, Lei
    Huang, Xiaobin
    Li, Yu
    Wu, Jin
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 938
  • [48] Development of MicroRNA-Based Therapeutics for Vascular Disease
    Jones, Kia J.
    Searles, Charles D.
    CIRCULATION RESEARCH, 2020, 127 (09) : 1179 - 1181
  • [49] microRNA-based predictor for diagnosis of frontotemporal dementia
    Magen, Iddo
    Yacovzada, Nancy-Sarah
    Warren, Jason D.
    Heller, Carolin
    Swift, Imogen
    Bobeva, Yoana
    Malaspina, Andrea
    Rohrer, Jonathan D.
    Fratta, Pietro
    Hornstein, Eran
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2023, 49 (04)
  • [50] The potential for microRNA-based therapeutics in retinal disorders
    Chu-Tan, Joshua A.
    Natoli, Riccardo
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (07)